close

Agreements

1 209 210 211 212 213 246
Number of results: 4911

PDF print is not allowed for data more than 3000.Please search above for fewer data.

Date Company Compound Disease Type of agreement Therapeutic area Type of Information
2012-10-30 Vivalis (France) undisclosed large, international animal health firm EB66® cell line

licensing

Veterinary medicine Licensing agreement
2012-10-30 Wacker Biotech (Germany) XL-protein (Germany) PASylated therapeutic proteins

collaboration
production
manufacturing

Production agreement
2012-10-29 Astex Pharmaceuticals (USA) Cancer Research Technology (UK) Newcastle University (UK) new cancer drugs cancer

R&D

Cancer - Oncology R&D agreement
2012-10-28 ViiV Healthcare (UK-USA) Shionogi (Japan) HIV integrase inhibitor portfolio, including dolutegravir HIV-Aids

development

commercialisation

Infectious diseases Development agreement
2012-10-26 Chugai Pharmaceutical (Japan) Kowa Company (Japan) Sanofi (France) SGLT2 Inhibitor “CSG452” - tofoglifozin type 2 diabetes

licensing
co-development

Metabolic diseases Licensing agreement
2012-10-25 Bayer (Germany) Qiagen (The Netherlands) companion diagnostics paired with novel Bayer HealthCare drugs cancer, various solid tumours

development
commercialisation

Cancer - Oncology Development agreement
2012-10-25 Red Glead Discovery (Sweden) SARomics Biostructures (Sweden) lead compounds against epigenetic pathway targets

R&D

R&D agreement
2012-10-25 Amgen (USA - CA) Kleiner Perkins Caufield & Byers (USA - CA) Atara Biotherapeutics (USA - CA)

licensing

creation of a new company

 

Cancer - Oncology - Kidney diseases - Renal diseases Licensing agreement
2012-10-24 Shire (UK) Fondazione Telethon (Italy) 13 undisclosed rare disease indications related to lysosomal storage disorders and neurodegenerative diseases

R&D

Rare diseases - Neurodegenerative diseases - Metabolic diseases R&D agreement
2012-10-24 Royal DSM (The Netherlands) Paranta Biosciences (Australia) follistatin respiratory diseases, inflammatory diseases

manufacturing
production

Respiratory diseases - Inflammatory diseases Production agreement
2012-10-23 Lonza (Switzerland) Oncomed Pharmaceuticals (USA) anti-cancer stem cell therapeutics including Demcizumab,Anti-Notch 2/3 (OMP-59R5), Anti-Fzd7 (OMP-18R5), Anti-Notch1 (OMP-52M51), Anti-DLL4/VEGF Bi-Specific

development
manufacturing
production

Cancer - Oncology Production agreement
2012-10-23 Theradiag (France) Sebia (France) undisclosed diagnostic kit undisclosed

development
manufacturing
production

undisclosed Development agreement
2012-10-23 Domain Therapeutics (France) Ono Pharmaceutical (Japan) small molecules targeting G-Protein Coupled Receptors (GPCRs) selected by Ono undisclosed

R&D

undisclosed R&D agreement
2012-10-23 Almirall (Spain) AB-Biotics (Spain) pharmacogenetic tests including Neurofarmagen

acquisition
commercialisation

Commercialisation agreement
2012-10-23 PolyTherics (UK) Biotecnol (USA) multi-specific Tribody Drug Conjugates (TDCs) cancer

development

Cancer - Oncology Development agreement
2012-10-23 Cellectis (France) NIH (USA) generation of induced pluripotent stem (iPS) cell lines of research grade and differentiation of iPS cells toward specific tissue cell type for research use

services

Services contract
2012-10-23 Fujifilm Diosynth Biotechnologies UK (UK) Piramal (india) antibody drug conjugates (ADCs)

manufacturing
production

Production agreement
2012-10-23 AstraZeneca (UK) Ironwood Pharmaceuticals (China) linaclotide irritable bowel syndrome with constipation (IBS-C) development -commercialisation - promotion Gastrointestinal diseases - Digestive diseases Development agreement
2012-10-22 Genzyme (USA - MA), a Sanofi company (France) - Alnylam Pharmaceuticals (USA - MA) RNAi therapeutics targeting transthyretin (TTR) transthyretin-mediated amyloidosis (ATTR) development - commercialisation Rare diseases - Genetic diseases Development agreement
2012-10-18 BioAlliance Pharma (France) Shafayab Gostar (Iran) Loramyc® (miconazole Lauriad™) oropharyngeal candidiasis in immunocompromised patients

distribution
commercialisation

Infectious diseases Distribution agreement